炎性相关标志物判断HBV相关慢加急性肝衰竭预后的研究进展

邓婷婷; 李莉; 关瀛; 罗雪艳; 秦坤; 刘敏

doi:10.3969/j.issn.1001-5256.2022.10.028

炎性相关标志物判断HBV相关慢加急性肝衰竭预后的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.10.028

邓婷婷¹,
李莉^{1, 2, , ,},
关瀛¹,
罗雪艳¹,
秦坤¹,
刘敏¹

1.
遵义医科大学第一临床学院，贵州遵义 563000
2.
贵州省遵义医科大学黔西南附属医院全科医学科，贵州兴义 562400

基金项目:

贵州省省长资金临床课题专项研究 (Qian Province Specialized Cooperation [2012] No. 113);

贵州省科技计划 (Qian Kehe SY [2013] No. 3029)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：邓婷婷、李莉负责拟定写作思路; 邓婷婷、关瀛、罗雪艳、秦坤、刘敏负责文献检索及资料分析; 邓婷婷、李莉负责文章撰写、修改及最后定稿。

详细信息

通信作者:
李莉，1444522659@qq.com

计量
- 文章访问数: 413
- HTML全文浏览量: 81
- PDF下载量: 71
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-01
- 录用日期: 2022-04-08
- 出版日期: 2022-10-20

Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure

Tingting DENG¹,
Li LI^{1, 2
, ,
,},
Ying GUAN¹,
Xueyan LUO¹,
Kun QIN¹,
Min LIU¹

1.
The First Clinical Institute, Zunyi Medical University, Zunyi, Guizhou 563000, China
2.
Department of General Medicine, Qianxinan Affiliated Hospital of Zunyi Medical University, Xingyi, Guizhou 562400, China

Research funding:

Special Research on Clinical Topics for Guizhou Provincial Governor's Funds (Qian Province Specialized Cooperation [2012] No. 113);

Science and Technology Plan of Guizhou Province (Qian Kehe SY [2013] No. 3029)

More Information

Corresponding author: LI Li, 1444522659@qq.com(ORCID: 0000-0003-2664-3832)

摘要

摘要: 慢加急性肝衰竭是一种短期急剧恶化、合并多器官功能衰竭且病死率高的临床综合症候群，是重症肝病研究领域的热点内容。早期、准确、快速判断临床预后，及时干预疾病进展对改善疾病转归具有重要意义。对近年来发现的HBV相关慢加急性肝衰竭炎性相关预后标志物进行了归纳，旨在完善现有预后指标，为临床医生评估慢加急性肝衰竭患者预后提供更多的依据。
- 乙型肝炎病毒 /
- 慢加急性肝功能衰竭 /
- 生物标记 /
- 预后
Abstract: Acute-on-chronic liver failure (ACLF) is a clinical syndrome with short-term rapid deterioration, multiple organ failure, and high mortality and has become a research hotspot in the field of severe liver diseases. Early, accurate, and quick judgment of clinical prognosis and timely intervention of disease progression are of great significance for improving disease outcome. This article summarizes the inflammation-related prognostic markers for HBV-related ACLF found in recent years, so as to improve the existing prognostic indicators and provide more basis for evaluating the prognosis of ACLF patients by clinicians.
- Hepatitis B Virus /
- Acute-On-Chronic Liver Failure /
- Biomarkers /
- Prognosis

HTML全文

参考文献(43)

[1]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
[2]	CHEN JJ, FAN LX, LI LJ. Interpretation of Diagnostic and treatment guidelines for liver failure (2018 edition)[J]. Chin J Clinicians, 2020, 48(11): 1279-1282. DOI: 10.3969/j.issn.2095-8552.2020.11.005. 陈佳佳, 范林骁, 李兰娟. 《肝衰竭诊治指南(2018版)》指南解读[J]. 中国临床医生杂志, 2020, 48(11): 1279-1282. DOI: 10.3969/j.issn.2095-8552.2020.11.005.
[3]	ZHANG H, JIA L, Yao SW, et al. Value of MELD combined with serum sodium concentration in predicting the short-term outcome of patients with HBV-related acute-on-chronic liver failure in China: A meta-analysis[J]. J Clin Hepatol, 2018, 34(9): 1950-1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024. 张辉, 贾雷, 姚士伟, 等. MELD-Na评分对我国HBV相关慢加急性肝衰竭短期预后预测价值的Meta分析[J]. 临床肝胆病杂志, 2018, 34(9): 1950-1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.
[4]	LI ZL, TONG XJ, TIAN WW, et al. Expression of interleukin-26 in patients with hepatitis B virus-related acute-on-chronic liver failure and its clinical significance[J]. Clin J Med Offic, 2020, 48(12): 1492-1493, 1496. DOI: 10.16680/j.1671-3826.2020.12.39. 李增莲, 仝晓净, 田稳稳, 等. 白细胞介素26在乙型肝炎病毒相关慢加急性肝衰竭患者中表达及临床意义[J]. 临床军医杂志, 2020, 48(12): 1492-1493, 1496. DOI: 10.16680/j.1671-3826.2020.12.39.
[5]	WANG TS, WANG N, ZHANG RZ, et al. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. J Clin Hepatol, 2020, 36(6): 1415-1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050. 王挺帅, 王娜, 张荣臻, 等. 免疫反应与炎症损伤在肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36(6): 1415-1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.
[6]	SUN J, GUO H, YU X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2021, 21(1): 422. DOI: 10.1186/s12876-021-02007-w.
[7]	BERNSMEIER C, CAVAZZA A, FATOUROU EM, et al. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure[J]. Aliment Pharmacol Ther, 2020, 52(5): 855-865. DOI: 10.1111/apt.15932.
[8]	BAO S, ZHENG J, LI N, et al. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage[J]. Clin Res Hepatol Gastroenterol, 2017, 41(2): 147-155. DOI: 10.1016/j.clinre.2016.10.005.
[9]	MO R, WANG P, LAI R, et al. Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure[J]. J Gastroenterol Hepatol, 2017, 32(3): 677-686. DOI: 10.1111/jgh.13537.
[10]	SCHWARZKOPF K, RVSCHENBAUM S, BARAT S, et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure[J]. Hepatol Commun, 2019, 3(3): 392-405. DOI: 10.1002/hep4.1303.
[11]	XIANG X, FENG D, HWANG S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice[J]. J Hepatol, 2020, 72(4): 736-745. DOI: 10.1016/j.jhep.2019.11.013.
[12]	DU XX, SHI Y, YANG Y, et al. DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure[J]. Liver Int, 2018, 38(2): 229-238. DOI: 10.1111/liv.13503.
[13]	YUAN W, MEI X, ZHANG YY, et al. High expression of interleukin-33/st2 predicts the progression and poor prognosis in chronic hepatitis B patients with hepatic flare[J]. Am J Med Sci, 2020, 360(6): 656-661. DOI: 10.1016/j.amjms.2020.06.023.
[14]	WU ZB, ZHENG YB, WANG K, et al. Plasma interleukin-6 level: A potential prognostic indicator of emergent HBV-associated ACLF[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5545181. DOI: 10.1155/2021/5545181.
[15]	ZHOU C, ZHANG N, HE TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure[J]. World J Gastroenterol, 2020, 26(30): 4479-4488. DOI: 10.3748/wjg.v26.i30.4479.
[16]	HE Y, FENG D, HWANG S, et al. Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes[J]. J Hepatol, 2021, 75(1): 163-176. DOI: 10.1016/j.jhep.2021.02.004.
[17]	LIU Y, MENG X, WANG C, et al. Interleukin-18 plays a positive feedback activity to natural killer-like B cells in hepatitis B virus-associated acute-on-chronic liver failure[J]. Viral Immunol, 2022, 35(1): 50-59. DOI: 10.1089/vim.2021.0164.
[18]	SHEN G, SUN S, HUANG J, et al. Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Hepatol Int, 2020, 14(1): 47-56. DOI: 10.1007/s12072-019-10008-x.
[19]	LI J, HU CH, CHEN Y, et al. Characteristics of peripheral lymphocyte subsets in patients with acute-on-chronic liver failure associated with hepatitis B[J]. Front Med (Lausanne), 2021, 8: 689865. DOI: 10.3389/fmed.2021.689865.
[20]	ZHANG GL, ZHANG T, ZHAO QY, et al. Increased IL-17-producing CD8⁺ T cell frequency predicts short-term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Ther Clin Risk Manag, 2018, 14: 2127-2136. DOI: 10.2147/TCRM.S184809.
[21]	ZHANG GL, ZHANG T, ZHAO QY, et al. Th17 cells over 5.9% at admission indicate poor prognosis in patients with HBV-related acute-on-chronic liver failure[J]. Medicine (Baltimore), 2018, 97(40): e12656. DOI: 10.1097/MD.0000000000012656.
[22]	TAN NH, CHEN B, PENG J, et al. Treg/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages[J]. Biomed Res Int, 2021, 2021: 9140602. DOI: 10.1155/2021/9140602.
[23]	LU YY, XIN JJ, DING WC, et al. Expression and diagnostic value of macrophage inflammatory protein-3α in patients with hepatitis B-related acute-on-chronic liver failure[J]. Chin J Hepatol, 2021, 29(12): 1156-1163. DOI: 10.3760/cma.j.cn501113-20210809-00386. 卢莺燕, 辛娇娇, 丁文超, 等. 巨噬细胞炎性蛋白-3α在乙型肝炎相关慢加急性肝衰竭患者中的表达及其诊断价值[J]. 中华肝脏病杂志, 2021, 29(12) : 1156-1163. DOI: 10.3760/cma.j.cn501113-20210809-00386.
[24]	WANG XL, CHEN XJ, YE HH, et al. Association of mRNA expression level of IP-10 in peripheral blood mononuclear cells with HBV-associated acute-on-chronic liver failure and its prognosis[J]. J Huazhong Univ Sci Technolog Med Sci, 2017, 37(5): 755-760. DOI: 10.1007/s11596-017-1800-2.
[25]	XIAO L, TANG S, ZHANG L, et al. Serum CXCL1 is a prognostic factor for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Front Med (Lausanne), 2021, 8: 657076. DOI: 10.3389/fmed.2021.657076.
[26]	ZHANG DN, LIU Y, LI X, et al. Imbalance between soluble and membrane-bound CD100 regulates monocytes activity in hepatitis B virus-associated acute-on-chronic liver failure[J]. Viral Immunol, 2021, 34(4): 273-283. DOI: 10.1089/vim.2020.0311.
[27]	ZHAO R, WU W, ZHOU Z, et al. Prognostic utility of novel biomarkers in acute-on-chronic liver failure (ACLF) associated with hepatitis B: A multicenter prospective study[J]. Hepatol Res, 2019, 49(1): 42-50. DOI: 10.1111/hepr.13251.
[28]	GRØNBAEK H, MØLLER HJ, SALIBA F, et al. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation[J]. J Gastroenterol Hepatol, 2021, 36(1): 240-248. DOI: 10.1111/jgh.15125.
[29]	JIA Y, MA L, WANG Y, et al. NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV-ACLF[J]. Mol Immunol, 2020, 120: 179-186. DOI: 10.1016/j.molimm.2020.01.011.
[30]	LI Z, JIANG J. The NLRP3 inflammasome mediates liver failure by activating procaspase-1 and pro-IL-1 β and regulating downstream CD40-CD40L signaling[J]. J Int Med Res, 2021, 49(9): 3000605211036845. DOI: 10.1177/03000605211036845.
[31]	BAI L, KONG M, DUAN Z, et al. M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis[J]. Cell Death Dis, 2021, 12(1): 93. DOI: 10.1038/s41419-020-03378-w.
[32]	ZHANG GL, ZHANG T, YE YN, et al. Complement factor 3 could be an independent risk factor for mortality in patients with HBV related acute-on-chronic liver failure[J]. Biomed Res Int, 2016, 2016: 3524842. DOI: 10.1155/2016/3524842.
[33]	LI Q, LU Q, ZHU MQ, et al. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2020, 20(1): 106. DOI: 10.1186/s12876-020-01258-3.
[34]	ZHOU N, WANG K, FANG S, et al. Discovery of a potential plasma protein biomarker panel for acute-on-chronic liver failure induced by hepatitis B virus[J]. Front Physiol, 2017, 8: 1009. DOI: 10.3389/fphys.2017.01009.
[35]	LI TP, GUAN SH, WANG Q, et al. Soluble mannose receptor as a predictor of prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2019, 25(37): 5667-5675. DOI: 10.3748/wjg.v25.i37.5667.
[36]	WANG K, ZHANG Z, MO ZS, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure[J]. Gut Microbes, 2021, 13(1): 1-15. DOI: 10.1080/19490976.2021.1921925.
[37]	MA S, XIE Z, ZHANG L, et al. Identification of a potential miRNA-mRNA regulatory network associated with the prognosis of HBV-ACLF[J]. Front Mol Biosci, 2021, 8: 657631. DOI: 10.3389/fmolb.2021.657631.
[38]	CISILOTTO J, DO AMARAL AE, ROSOLEN D, et al. MicroRNA profiles in serum samples from acute-on-chronic liver failure patients and miR-25-3p as a potential biomarker for survival prediction[J]. Sci Rep, 2020, 10(1): 100. DOI: 10.1038/s41598-019-56630-5.
[39]	LIU H, LI Y, GAO F, et al. Serum clusterin: A potential marker for assessing the clinical severity and short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Dis Markers, 2020, 2020: 8814841. DOI: 10.1155/2020/8814841.
[40]	WU D, ZHANG S, XIE Z, et al. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure[J]. J Clin Invest, 2020, 130(4): 2069-2080. DOI: 10.1172/JCI130197.
[41]	SUN Z, LIU X, WU D, et al. Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B[J]. Theranostics, 2019, 9(4): 1200-1214. DOI: 10.7150/thno.31991.
[42]	JUANOLA A, GRAUPERA I, ELIA C, et al. Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis[J]. J Hepatol, 2022, 76(1): 107-114. DOI: 10.1016/j.jhep.2021.08.031.
[43]	LI J, LIANG X, JIANG J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2022, 71(1): 163-175. DOI: 10.1136/gutjnl-2020-323395.